Rigel Pharmaceuticals, Inc. (RIGL) Financials

RIGL Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 521.1 million 95.4 million
March 31, 2026 504.6 million 104.7 million
Dec. 31, 2025 513.6 million 122.1 million
Sept. 30, 2025 242.5 million 124.9 million

RIGL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 33.4 million 10.3 million
March 31, 2026 2.7 million 3.5 million
Dec. 31, 2025 22.0 million 2.7 million
Sept. 30, 2025 24.0 million 3.4 million

RIGL Net Income

No data available :(

RIGL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 95.3 million - 714000
March 31, 2026 146.7 million 15.0 million 864000
Dec. 31, 2025 155.0 million 22.5 million 395000
Sept. 30, 2025 137.1 million 30.0 million 1.2 million

RIGL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 19.6 million
March 31, 2026 19.7 million
Dec. 31, 2025 18.8 million
Sept. 30, 2025 19.2 million

RIGL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 14.0 million 32.6 million -
March 31, 2026 - 11.7 million 30.7 million -
Dec. 31, 2025 12000 10.7 million 30.0 million -
Sept. 30, 2025 12000 7.4 million 28.9 million -

RIGL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 78.7 million 8.5 million
March 31, 2026 58.8 million 4.6 million
Dec. 31, 2025 69.8 million 6.0 million
Sept. 30, 2025 69.5 million 4.8 million

RIGL Revenue by Segment
Graph available only for paid members. Upgrade to see it.

RIGL

Price: $43.62

52 week price:
24.95
52.24

Earnings Per Share: 16.89 USD

P/E Ratio: 2.38

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 2.8 million

Ebitda: -17.7 million

Market Capitalization: 750.4 million

Links: